Diligence memo · auto-generated · as of July 2, 2026
ARCA biopharma, Inc.
ARCA biopharma, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
ARCA biopharma, Inc. operates in Pharmaceuticals, based in WESTMINSTER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ARCA biopharma, Inc. has raised $60M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $52M on 2015-06-16.
Most recent recorded round closed around 2015-06-16.
Valuation (modeled)modeled
Provath models ARCA biopharma, Inc. at approximately $1.8B (range $168M–$4.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.88× the median modeled value of Series C Pharmaceuticals companies in 2013–2015 (19 peers) — value vs value, same stage and era. Within the normal band (88% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 11.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 158.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Bellicum Pharmaceuticals, Inc, Paratek Pharmaceuticals Inc, Turing Pharmaceuticals AG, Seres Health, Inc., Syndax Pharmaceuticals Inc.
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.